2014 ACRUX AGM 27/11/14 from the chairman:
The viability of our process was proven during the development of the two projects with Hexima. We are confident that the new intellectual property developed jointly with Hexima and other intellectual property independently owned by Acrux will create significant shareholder value.
Financial Report half year ended 31 December 2014 – 26/02/15 The Directors regularly review projects and will update the market when progress is made. The two Hexima projects remain on hold, pending resolution of our dispute.
Financial Report full year ended 30 June 2015 – 13/08/15 the result of investment in the consolidated entities strategy coupled with legal costs incurred in the dispute with Hexima.
2015 Annual Report We continue to progress development of an antifungal therapeutic for onychomycosis. Subject to the results
of work currently being undertaken as part of the development program, new intellectual property is expected to be generated. In a separate initiative, we have made significant progress with superior formulations of two nonsteroidal anti-inflammatory drugs.
So nothing regarding what the terms of the final agreement were, who got what as far as the IP or R&D benefits that had accrued to date and what if any payments were required by either party.
ACR Price at posting:
15.5¢ Sentiment: None Disclosure: Held
